title: The vascular and biochemical effects of cilostazol in diabetic patients with peripheral arterial disease.
abstract: OBJECTIVE
  Cilostazol improves walking in patients with peripheral arterial disease (PAD). We hypothesized that cilostazol reduces diabetic complications in PAD patients.
  
  
  METHODS
  Diabetic PAD patients were prospectively recruited to a randomized double-blinded, placebo-controlled trial, using cilostazol 100mg twice a day. Clinical assessment included ankle-brachial index, arterial compliance, peripheral transcutaneous oxygenation, treadmill walking distance and validated quality of life (QoL) questionnaires. Biochemical analyses included glucose and lipid profiles. All tests were at baseline, 6, and 24 weeks.
  
  
  RESULTS
  26 diabetic PAD patients (20 men) were recruited. Cilostazol improved absolute walking distance at 6 and 24 weeks (86.4% vs. 14.1%, P = .049; 143% vs. 23.2%, P = .086). Arterial compliance and lipid profiles improved as did some QoL indices for cilostazol at 6 and 24 weeks. Blood indices were similar at baseline and at follow-up points for both treatment groups.
  
  
  CONCLUSIONS
  Cilostazol is a well-tolerated and efficacious treatment, which improves claudication distances in diabetic PAD patients with further benefits in arterial compliance, lipid profiles, and QoL.
authors.affiliation: Department of Vascular and Endovascular Surgery, Belfast City Hospital, Northern Ireland, United Kingdom. modonnell904@hotmail.com
authors.forename: Mark E
authors.initials: ME
authors.lastname: O'Donnell
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Badger
authors.forename: Muhammad A
authors.initials: MA
authors.lastname: Sharif
authors.forename: Ragai R
authors.initials: RR
authors.lastname: Makar
authors.forename: Ian S
authors.initials: IS
authors.lastname: Young
authors.forename: Bernard
authors.initials: B
authors.lastname: Lee
authors.forename: C V
authors.initials: CV
authors.lastname: Soong
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000842:Ankle / Q000098:blood supply; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure; D001916:Brachial Artery / Q000503:physiopathology; D002317:Cardiovascular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D000077407:Cilostazol; D003187:Compliance; D003925:Diabetic Angiopathies / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D004311:Double-Blind Method; D005260:Female; D006442:Glycated Hemoglobin / Q000378:metabolism; D006801:Humans; D007328:Insulin / Q000097:blood; D007383:Intermittent Claudication / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D010100:Oxygen / Q000097:blood; D016491:Peripheral Vascular Diseases / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D011446:Prospective Studies; D011788:Quality of Life; D011795:Surveys and Questionnaires; D013777:Tetrazoles / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D016138:Walking
chemical_list: D015415:Biomarkers; D001786:Blood Glucose; D002317:Cardiovascular Agents; D000077407:Cilostazol; D006442:Glycated Hemoglobin; D007328:Insulin; D008055:Lipids; D010100:Oxygen; D013777:Tetrazoles; C517652:hemoglobin A1c protein, human